Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Neon Therapeutics, Inc.    NTGN

NEON THERAPEUTICS, INC.

(NTGN)
  Report
 SummaryQuotesNewsRatingsCalendarCompanyFinancials 
Financials (USD)
Sales 2018 - - -
Net income 2018 -76,9 M - -
Net cash position 2018 103 M - -
P/E ratio 2018 -0,91x
Yield 2018 -
Sales 2019 - - -
Net income 2019 -79,8 M - -
Net cash position 2019 21,6 M - -
P/E ratio 2019 -0,41x
Yield 2019 -
Capitalization 88,9 M 88,9 M -
EV / Sales 2018 -
EV / Sales 2019 -
Nbr of Employees 71
Free-Float 87,5%
More Financials
Company
Neon Therapeutics is a clinical-stage immuno-oncology company. The Company is focused on developing therapeutics leveraging neoantigen biology to treat cancer. The Company's neoantigen-based product engine allows it to develop multiple treatment modalities, including vaccines and thymus (T) cell therapies targeting both personalized and shared neoantigens. The Company's neoantigen-based product engine targets both... 
More about the company
Surperformance© ratings of Neon Therapeutics, Inc.
Trading Rating : Investor Rating : -
More Ratings
Latest news on NEON THERAPEUTICS, INC.
05/06NEON THERAPEUTICS, INC. : Change in Directors or Principal Officers (form 8-K)
AQ
05/05NEON THERAPEUTICS, INC. : Submission of Matters to a Vote of Security Holders (f..
AQ
04/30Neon Therapeutics Announces Acceptance of European Clinical Trial Authorizati..
GL
04/29NEON THERAPEUTICS, INC. : Other Events (form 8-K)
AQ
03/18INFINITY PHARMACEUTICALS : Augments Board of Directors with Appointment of Richa..
AQ
03/02NEON THERAPEUTICS : Management's Discussion and Analysis of Financial Condition ..
AQ
03/02NEON THERAPEUTICS, INC. : Results of Operations and Financial Condition (form 8-..
AQ
03/02NEON THERAPEUTICS : Reports Fourth Quarter and Full Year 2019 Financial Results ..
AQ
01/28NEON THERAPEUTICS INVESTOR ALERT BY : Kahn Swick & Foti, LLC Investigates Adequ..
BU
01/16NEON THERAPEUTICS, INC. : Entry into a Material Definitive Agreement, Other Even..
AQ
2019NEON THERAPEUTICS : Submits European Clinical Trial Authorization Application fo..
AQ
2019NEON THERAPEUTICS, INC. : Costs Associated with Exit or Disposal Activities (for..
AQ
2019Neon Therapeutics Announces New Strategic Focus on Novel T Cell Programs
GL
2019NEON THERAPEUTICS, INC. : Results of Operations and Financial Condition (form 8-..
AQ
2019Neon Therapeutics Reports Third Quarter 2019 Financial Results and Recent Hig..
GL
More news
News in other languages on NEON THERAPEUTICS, INC.
01/16Biotechfirma BioNTech kauft US-Krebsspezialisten
More news
Chart NEON THERAPEUTICS, INC.
Duration : Period :
Neon Therapeutics, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Income Statement Evolution
Managers
NameTitle
Yasir B. Al-Wakeel Chief Financial Officer
Richard B. Gaynor President-Research & Development
Jolie M. Siegel Secretary, General Counsel & VP
Teresa Regan Chief People & Culture Officer
Sector and Competitors
1st jan.Capitalization (M$)
NEON THERAPEUTICS, INC.160.17%89
GILEAD SCIENCES12.62%91 795
VERTEX PHARMACEUTICALS21.72%69 097
REGENERON PHARMACEUTICALS45.20%60 715
WUXI APPTEC CO., LTD.13.36%25 297
GENMAB A/S41.82%20 190